Myasthenia Gravis, Myasthenia Gravis Crisis
Conditions
Keywords
Myasthenia Gravis, Prognostic prediction
Brief summary
The average annual incidence of Myasthenia gravis is up to (8.0-20.0) / 100,000 people. Myasthenia gravis is an acquired autoimmune disease. All skeletal muscles of patients may be involved. When ocular muscles are involved, ptosis, diplopia and other symptoms may occur. When the laryngopharyngeal muscles are involved, the patient may develop dysarthria, dysphagia and other symptoms. However, when the respiratory muscles are involved, patients will have difficulty in breathing, and some patients may develope myasthenia crisis, and artificial assisted respiratory therapy is often needed. This study is a prospective observational study, in which patients are continuously enrolled, basic information of patients is collected, and biological samples are collected. The purpose of this study is to improve the diagnosis and prognosis of myasthenia gravis patients.
Interventions
DEVICEbiomarkers
biomarkers
Sponsors
First Affiliated Hospital of Chongqing Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 80 Years
Healthy volunteers
No
Inclusion criteria
* Meeting the diagnosis of myasthenia gravis
Exclusion criteria
* Malignant tumor or other serious chronic disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Myasthenia gravis foundation of America post intervention status | 3 years | Complete Stable Remission (CSR) Pharmacologic Remission (PR) Minimal Manifestations (MM) Change in Status: Improved (I) Unchanged (U) Worse (W) Exacerbation (E) Died of MG (D of MG) |
Countries
China
Contacts
Primary ContactFei Xiao, MD
Outcome results
None listed